Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Anaadriana Zakarija, MD, Thanh Ha Luu, Hau C. Kwaan, MD, PhD, June McKoy, MD, JD, MPH, Ivy Weiss, BS, Paul Yarnold, Nicholas Bandarenko, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 892.

https://doi.org/10.1182/blood.V114.22.892.892

Published: 2009

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Monica Boen, BA, June McKoy, MD, MPH, Dennis West, Beatrice Edwards, Jayesh Mehta, Seema Singhal, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2403.

https://doi.org/10.1182/blood.V112.11.2403.2403

Published: 2008

Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4681.

https://doi.org/10.1182/blood.V112.11.4681.4681

Published: 2008

Journal Articles

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Veena Shankaran, MD, June McKoy, MD, MPH, JD, Ben Djulbegovic, MD, PhD, Allison Lyons, BA, Ken Carson, MD, Cara Tigue, BA, Neal Dandade, BA, Martin Tallman, MD, Oliver Sartor, MD, Charles Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3340.

https://doi.org/10.1182/blood.V110.11.3340.3340

Published: 2007

Journal Articles

Subacute Thrombotic Events Associated with Drug Eluting Cardiac Stents May Be Localized Hypersensitivity Reactions to Polymers.

Charles Bennett, MD, PhD, Jonathan Nebeker, MD, Renu Virmani, MD, June McKoy, MD, JD, MPH, Jenny Hoffman, MD, Dennis Raisch, PhD, Dennis West, MD, Matthew Samore, MD, Paul Yarnold, PhD, Charles Davidson, MD, Steven Belknap, MD, Marc Feldman, MD6

Blood (2004) 104 (11): 2198.

https://doi.org/10.1182/blood.V104.11.2198.2198

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Subacute Thrombotic Events Associated with Drug Eluting Cardiac Stents May Be Localized Hypersensitivity Reactions to Polymers.

Email alerts

ASH Publications

American Society of Hematology

Update search

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Waiting for Godot: Thirty-Six Month Follow-Up on Accelerated FDA Approval of Drugs To Treat Hematologic Malignancies.

Subacute Thrombotic Events Associated with Drug Eluting Cardiac Stents May Be Localized Hypersensitivity Reactions to Polymers.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only